| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Omeros Corporation | Zaltenibart - (OMS906) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Enrollment Initiation | Intravenous | Hematology |
| Omeros Corporation | Narsoplimab (I-SPY COVID-19) | COVID-19 | Phase 2 | Trial Discontinued | Intravenous | COVID-19 |
| OmniAb Inc. | Batoclimab (IMVT-1401) | Myasthenia Gravis (MG) | Phase 3 | Data Released | Subcutaneous | Neurology |
| OmniAb Inc. | Batoclimab | Graves' Disease | Phase 3 | Trial Planned | Intravenous | Endocrinology |
| OmniAb Inc. | Batoclimab (IMVT-1401) | Myasthenia Gravis (MG) | Phase 3 | Data Released | Subcutaneous | Neurology |
| OmniAb Inc. | Batoclimab | Thyroid Eye Disease (TED) | Phase 3 | Ongoing | Intravenous | Opthalmic |
| Oncolytics Biotech Inc. | Pelareorep and retifanlimab (INCMGA00012) - (IRENE) | Triple-negative breast cancer | Phase 2 | Trial Completed | Intravenous | Oncology |
| Oncolytics Biotech Inc. | Pelareorep, (Taxol) paclitaxel and BAVENCIO (avelumab) - (BRACELET-1) | HR+ / HER2- breast cancer | Phase 2 | Data Released | Intravenous | Oncology |